Stock Fundamentals

AI Research Report

Generate a comprehensive financial analysis report powered by AI

BMRN.US Logo

BMRN.US - Current Price

$57.71

Company Information

Company Name
Biomarin Pharmaceutical Inc
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
ISIN: US09061G1013
CIK: 0001048477
CUSIP: 09061G101
Currency: USD
Full Time Employees: 3,040
Phone: 415 506 6700
Fiscal Year End: December
IPO Date: Jul 23, 1999
Description:

BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally. The company's products include VIMIZIM, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; VOXZOGO, a once daily injection analog of c-type natriuretic peptide (CNP) for the treatment of achondroplasia; NAGLAZYME, a recombinant form of N- acetylgalactosamine 4-sulfatase for patients with MPS VI; and PALYNZIQ, a PEGylated recombinant phenylalanine (Phe) ammonia lyase enzyme delivered through subcutaneous injection to reduce blood Phe concentrations. It also develops BRINEURA, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; ALDURAZYME, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase; KUVAN, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria, an inherited metabolic disease; and ROCTAVIAN, an adeno associated virus vector for the treatment of severe hemophilia A. The company's products under development include BMN 333, a longer-acting CNP for the treatment of multiple growth disorders, such as achondroplasia and hypochondroplasia; BMN 349, an oral therapeutic for the treatment of liver disease associated with alpha-1 antitrypsin deficiency; and BMN 351, an oligonucleotide for the treatment of duchenne muscular dystrophy. It serves specialty pharmacies, hospitals, non-U.S. government agencies, distributors, and pharmaceutical wholesalers. The company has license and collaboration agreements with Catalyst Pharmaceutical Partners, Inc., and Ares Trading S.A. The company was incorporated in 1996 and is based in San Rafael, California.

Address:

770 Lindaro Street, San Rafael, CA, United States, 94901

Directors & Officers

Name Title Year Born
Mr. Alexander Hardy President, CEO & Director 1968
Mr. Brian R. Mueller CPA CFO & Executive VP 1974
Mr. George Eric Davis J.D. Executive VP, Chief Legal Officer & Secretary 1971
Ms. Cristin Hubbard Executive VP & Chief Commercial Officer NA
Dr. Gregory Friberg M.D. Executive VP and Chief Research & Development Officer NA
Dr. C. Greg Guyer Ph.D. Executive VP & CTO 1962
Dr. Kevin Eggan Ph.D. Chief Scientific Officer & Senior VP of Research and Early Development NA
Ms. Amy Wireman Executive VP & Chief People Officer NA
Dr. Ganesh Vedantham Ph.D. Senior Vice President of Technical Development NA
Ms. Marni Kottle Executive VP & Chief Corporate Affairs Officer NA

Shares Statistics

Shares Outstanding: 192.11M
Shares Float: 190.50M
% Insiders: 74.80%
% Institutions: 9,887.10%
Short % Float: 5.37%

Valuation Metrics

Enterprise Value: $10.45B
Trailing P/E: 21.45
Forward P/E: 11.17

Financial Highlights

Market Cap: $11.09B
EBITDA: $794.05M
P/E Ratio: $21.45
PEG Ratio: $0.45
Book Value: $31.53
Earnings/Share: $2.69
Profit Margin: 16.82%
Operating Margin: -6.02%
ROA (TTM): 6.15%
ROE (TTM): 9.07%
Revenue (TTM): $3.09B
Revenue/Share (TTM): $16.17
Earnings Growth (YOY): 124.30%
Revenue Growth (YOY): 4.10%

Stock Price History

1 Year Price History

2 Years Price History

5 Years Price History

10 Years Price History

Financial Charts

Revenue & Net Income

Operating Expenses

Balance Sheet Overview

Earnings Per Share (EPS)

Earnings History

Date EPS Actual EPS Estimate Difference Surprise %
Dec 31, 2025 0.00 0.81 N/A -10,000.00%
Sep 30, 2025 0.12 0.82 N/A -8,542.45%
Jun 30, 2025 1.44 0.83 N/A 7,349.40%
Mar 31, 2025 1.13 0.65 N/A 7,339.27%
Dec 31, 2024 0.92 0.74 N/A 2,456.00%
Sep 30, 2024 0.55 0.52 N/A 576.92%
Jun 30, 2024 0.56 0.35 N/A 6,000.00%
Mar 31, 2024 0.46 0.35 N/A 3,142.86%
Dec 31, 2023 0.18 0.23 N/A -2,173.91%
Sep 30, 2023 0.21 0.23 N/A -869.57%
Jun 30, 2023 0.29 0.23 N/A 2,608.70%
Mar 31, 2023 0.27 0.18 N/A 5,000.00%
Dec 31, 2022 0.00 -0.07 N/A 9,814.29%
Sep 30, 2022 -0.04 -0.01 N/A -30,000.00%
Jun 30, 2022 0.15 0.11 N/A 3,636.36%
Mar 31, 2022 0.18 0.17 N/A 588.24%
Dec 31, 2021 -0.32 -0.32 N/A 0.00%
Sep 30, 2021 -0.20 -0.25 N/A 2,000.00%
Jun 30, 2021 0.07 -0.11 N/A 16,363.64%
Mar 31, 2021 0.09 -0.07 N/A 22,857.14%
Dec 31, 2020 0.12 -0.19 N/A 16,315.79%
Sep 30, 2020 4.01 1.24 N/A 22,338.71%
Jun 30, 2020 -0.02 -0.10 N/A 8,000.00%
Mar 31, 2020 0.44 0.05 N/A 78,000.00%
Dec 31, 2019 0.08 -0.06 N/A 23,333.33%
Sep 30, 2019 0.30 0.06 N/A 40,000.00%
Jun 30, 2019 -0.21 -0.11 N/A -9,090.91%
Mar 31, 2019 -0.32 -0.19 N/A -6,842.11%
Dec 31, 2018 -0.02 -0.25 N/A 9,200.00%
Sep 30, 2018 -0.07 -0.22 N/A 6,818.18%
Jun 30, 2018 -0.21 -0.17 N/A -2,352.94%
Mar 31, 2018 -0.25 -0.17 N/A -4,705.88%
Dec 31, 2017 -0.40 -0.23 N/A -7,391.30%
Sep 30, 2017 -0.07 -0.14 N/A 5,000.00%
Jun 30, 2017 -0.21 -0.21 N/A 0.00%
Mar 31, 2017 -0.09 -0.29 N/A 6,896.55%
Dec 31, 2016 -0.53 -0.38 N/A -3,947.37%
Sep 30, 2016 -0.26 -0.39 N/A 3,333.33%
Jun 30, 2016 1.08 -0.52 N/A 30,769.23%
Mar 31, 2016 -0.53 -0.84 N/A 3,690.48%
Dec 31, 2015 0.39 0.99 N/A -6,060.61%
Sep 30, 2015 -0.57 -0.65 N/A 1,230.77%
Jun 30, 2015 -0.43 -0.53 N/A 1,886.79%
Mar 31, 2015 -0.38 -0.53 N/A 2,830.19%
Dec 31, 2014 -0.47 -0.59 N/A 2,033.90%
Sep 30, 2014 -0.38 -0.23 N/A -6,521.74%
Jun 30, 2014 -0.22 -0.42 N/A 4,761.90%
Mar 31, 2014 -0.33 -0.46 N/A 2,826.09%
Dec 31, 2013 -0.43 -0.35 N/A -2,285.71%
Sep 30, 2013 -0.38 -0.30 N/A -2,666.67%
Jun 30, 2013 -0.15 -0.29 N/A 4,827.59%
Mar 31, 2013 -0.31 -0.29 N/A -689.66%
Dec 31, 2012 -0.43 -0.27 N/A -5,925.93%
Sep 30, 2012 -0.04 -0.20 N/A 8,000.00%
Jun 30, 2012 -0.27 -0.21 N/A -2,857.14%
Mar 31, 2012 -0.21 -0.14 N/A -5,000.00%
Dec 31, 2011 -0.23 -0.11 N/A -10,909.09%
Sep 30, 2011 -0.14 -0.11 N/A -2,727.27%
Jun 30, 2011 -0.05 -0.11 N/A 5,454.55%
Mar 31, 2011 -0.04 -0.10 N/A 6,000.00%
Dec 31, 2010 0.01 -0.02 N/A 15,000.00%
Sep 30, 2010 1.68 -0.01 N/A 1,690,000.00%
Jun 30, 2010 -0.01 0.03 N/A -13,333.33%
Mar 31, 2010 0.01 N/A N/A N/A
Dec 31, 2009 0.05 0.01 N/A 40,000.00%
Sep 30, 2009 0.06 0.01 N/A 50,000.00%
Jun 30, 2009 0.01 -0.01 N/A 20,000.00%
Mar 31, 2009 -0.13 -0.12 N/A -833.33%
Dec 31, 2008 0.21 0.26 N/A -1,923.08%
Sep 30, 2008 0.01 0.03 N/A -6,666.67%
Jun 30, 2008 0.04 0.03 N/A 3,333.33%
Mar 31, 2008 0.02 -0.05 N/A 14,000.00%
Dec 31, 2007 0.03 0.04 N/A -2,500.00%
Sep 30, 2007 -0.05 -0.10 N/A 5,000.00%
Jun 30, 2007 -0.04 -0.06 N/A 3,333.33%
Mar 31, 2007 -0.10 -0.11 N/A 909.09%
Dec 31, 2006 -0.11 -0.13 N/A 1,538.46%
Sep 30, 2006 -0.08 -0.13 N/A 3,846.15%
Jun 30, 2006 -0.02 -0.11 N/A 8,181.82%
Mar 31, 2006 -0.13 -0.21 N/A 3,809.52%
Dec 31, 2005 -0.20 -0.22 N/A 909.09%
Sep 30, 2005 -0.21 -0.28 N/A 2,500.00%
Jun 30, 2005 -0.33 -0.35 N/A 571.43%
Mar 31, 2005 -0.35 -0.35 N/A 0.00%
Dec 31, 2004 -0.23 -0.33 N/A 3,030.30%
Sep 30, 2004 -0.40 -0.36 N/A -1,111.11%
Jun 30, 2004 -0.28 -0.29 N/A 344.83%
Mar 31, 2004 -0.31 -0.31 N/A 0.00%
Dec 31, 2003 -0.40 -0.38 N/A -526.32%
Sep 30, 2003 -0.33 -0.39 N/A 1,538.46%
Jun 30, 2003 -0.14 -0.16 N/A 1,250.00%
Mar 31, 2003 -0.35 -0.28 N/A -2,500.00%
Dec 31, 2002 -0.36 -0.35 N/A -285.71%
Sep 30, 2002 -0.32 -0.31 N/A -322.58%
Jun 30, 2002 -0.27 -0.29 N/A 689.66%
Mar 31, 2002 -0.51 -0.33 N/A -5,454.55%
Dec 31, 2001 -0.34 -0.30 N/A -1,333.33%
Sep 30, 2001 -0.26 -0.30 N/A 1,333.33%
Jun 30, 2001 -0.30 -0.26 N/A -1,538.46%
Mar 31, 2001 -0.26 -0.26 N/A 0.00%
Dec 31, 2000 -0.28 -0.33 N/A 1,515.15%
Sep 30, 2000 -0.23 -0.29 N/A 2,068.97%
Jun 30, 2000 -0.19 -0.27 N/A 2,962.96%
Mar 31, 2000 -0.34 -0.26 N/A -3,076.92%
Dec 31, 1999 -0.26 -0.26 N/A 0.00%
Sep 30, 1999 -0.24 -0.22 N/A -909.09%

Balance Sheet (Yearly)

Date Cash Total Debt Total Assets Total Liabilities Total Equity
2024-12-31 $942.84M $N/A $6.99B $1.33B $5.66B
2023-12-31 $755.13M $N/A $6.84B $1.89B $4.95B
2022-12-31 $724.53M $N/A $6.38B $1.77B $4.60B
2021-12-31 $587.28M $N/A $6.00B $1.73B $4.27B
2020-12-31 $649.16M $N/A $5.85B $1.74B $4.11B
2019-12-31 $437.45M $N/A $4.69B $1.57B $3.12B
2018-12-31 $493.98M $N/A $4.43B $1.46B $2.97B
2017-12-31 $598.03M $N/A $4.63B $1.82B $2.81B
2016-12-31 $408.33M $N/A $4.02B $1.26B $2.77B
2015-12-31 $397.04M $N/A $3.73B $1.33B $2.40B
2014-12-31 $875.49M $N/A $2.49B $962.56M $1.53B
2013-12-31 $568.78M $N/A $2.24B $903.02M $1.34B
2012-12-31 $180.53M $N/A $1.57B $552.58M $1.02B
2011-12-31 $46.27M $N/A $1.31B $532.66M $773.05M
2010-12-31 $88.08M $N/A $1.26B $545.37M $717.26M
2009-12-31 $167.17M $N/A $917.16M $594.98M $322.19M
2008-12-31 $222.90M $N/A $906.70M $630.02M $276.68M
2007-12-31 $228.34M $N/A $815.28M $627.55M $187.73M
2006-12-31 $89.16M $N/A $463.44M $345.63M $117.80M
2005-12-31 $38.09M $N/A $195.30M $272.77M $-77.46M
2004-12-31 $13.08M $N/A $232.97M $300.94M $-67.98M
2003-12-31 $121.41M $N/A $256.34M $138.49M $117.85M
2002-12-31 $33.64M $N/A $110.62M $12.07M $98.54M
2001-12-31 $12.53M $N/A $171.81M $12.26M $159.55M
2000-12-31 $16.53M $N/A $76.93M $6.94M $69.99M
1999-12-31 $23.41M $N/A $103.55M $5.17M $98.38M
1998-12-31 $9.40M $N/A $31.51M $2.11M $29.40M

Insider Trading

Date Insider Name Title Transaction Type Shares Price Value
May 20, 2025 N/A N/A N/A N/A N/A N/A
May 02, 2025 N/A N/A N/A N/A N/A N/A
Mar 19, 2025 N/A N/A N/A N/A N/A N/A
Feb 24, 2025 N/A N/A N/A N/A N/A N/A
Nov 12, 2024 N/A N/A N/A N/A N/A N/A

Watchlist

0

No stocks in watchlist